Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin C Collins

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2017
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation TherapyHimisha Beltran, Alexander W Wyatt, Edmund C Chedgy, et al.
Oncotarget|December 30, 2014
Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancerDong Lin, Xin Dong, Kendric Wang, et al.
Genes, Chromosomes & Cancer|August 29, 2012
Poly-gene fusion transcripts and chromothripsis in prostate cancerChunxiao Wu, Alexander W Wyatt, Andrew McPherson, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2025
AR-V7 condensates drive androgen-independent transcription in castration resistant prostate cancerShabnam Massah, Nicholas Pinette, Jane Foo, et al.
International Journal of Molecular Sciences|February 27, 2026
Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on <i>KRAS/NF1</i> Mutational StatusMadison Bittner, Marta Llaurado Fernandez, Joshua Hoenisch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2017
Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder CancerGillian Vandekerkhove, Tilman Todenhöfer, Matti Annala, et al.
Clinical Epigenetics|February 16, 2016
Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancerPier-Luc Clermont, Francesco Crea, Yan Ting Chiang, et al.
Cancer Research|March 1, 2018
Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate CancerXinpei Ci, Jun Hao, Xin Dong, et al.
Molecular Cancer Therapeutics|August 28, 2020
Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder CancerYoshihisa Kawai, Kenjiro Imada, Shusuke Akamatsu, et al.
Translational Oncology|November 7, 2025
Establishment and characterization of preclinical models of human gynecologic tract carcinosarcomas demonstrates targetable FGFR1 alterationsNelson K Y Wong, Marta Llaurado Fernandez, Hannah Kim, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2017
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation TherapyHimisha Beltran, Alexander W Wyatt, Edmund C Chedgy, et al.
Oncotarget|December 30, 2014
Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancerDong Lin, Xin Dong, Kendric Wang, et al.
Genes, Chromosomes & Cancer|August 29, 2012
Poly-gene fusion transcripts and chromothripsis in prostate cancerChunxiao Wu, Alexander W Wyatt, Andrew McPherson, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2025
AR-V7 condensates drive androgen-independent transcription in castration resistant prostate cancerShabnam Massah, Nicholas Pinette, Jane Foo, et al.
International Journal of Molecular Sciences|February 27, 2026
Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on <i>KRAS/NF1</i> Mutational StatusMadison Bittner, Marta Llaurado Fernandez, Joshua Hoenisch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2017
Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder CancerGillian Vandekerkhove, Tilman Todenhöfer, Matti Annala, et al.
Clinical Epigenetics|February 16, 2016
Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancerPier-Luc Clermont, Francesco Crea, Yan Ting Chiang, et al.
Cancer Research|March 1, 2018
Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate CancerXinpei Ci, Jun Hao, Xin Dong, et al.
Molecular Cancer Therapeutics|August 28, 2020
Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder CancerYoshihisa Kawai, Kenjiro Imada, Shusuke Akamatsu, et al.
Translational Oncology|November 7, 2025
Establishment and characterization of preclinical models of human gynecologic tract carcinosarcomas demonstrates targetable FGFR1 alterationsNelson K Y Wong, Marta Llaurado Fernandez, Hannah Kim, et al.
Pageof 10